News
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback